v3.26.1
Revenues
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
Product Revenue, Net
The Company’s product revenue is derived from the sales of its commercial products in Greater China. The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Product revenue - gross113,675 116,530 215,929 228,863 
Less: Rebates and sales returns(7,924)(7,445)(14,622)(14,128)
Product revenue - net105,751 109,085 201,307 214,735 
Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of product revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories.
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
ZEJULA32,079 41,042 62,046 90,571 
VYVGART / VYVGART Hytrulo23,866 26,497 41,417 44,602 
NUZYRA17,097 14,292 33,359 29,410 
OPTUNE12,202 12,355 24,272 23,718 
QINLOCK9,590 8,536 18,575 17,045 
XACDURO7,957 4,622 16,529 5,739 
AUGTYRO2,213 1,399 4,005 3,025 
KarXT552 — 552 — 
Other (i)195 342 552 625 
Product revenue - net105,751 109,085 201,307 214,735 
(i)Other includes product candidates sold in patient programs prior to commercialization.
Collaboration Revenue
Collaboration revenue was $0.6 million and $4.6 million in the three and six months ended June 30, 2026 and $0.9 million and $1.7 million in the three and six months ended June 30, 2025, respectively, and mainly related to a regional license and collaboration arrangement and promotional activities in mainland China.